

NEWSLETTER

CHEMICAL & PHARMACEUTICAL

10 - 16 August 2026



Pakistan Launches Anti-Dumping Probes into Chinese Chemical Exports

Pakistan's National Tariff Commission initiated anti-dumping investigations into imports of Chinese soda ash, ibuprofen, and composite aluminum foil following petitions from local manufacturers. Covering basic chemicals, active pharmaceutical ingredients, and packaging materials, the probes span investigation periods from 2023 to 2026. Preliminary determinations are expected within 60 to 180 days. **(ChemNet Chemical Headlines)**

South Korea Imposes Final Anti-Dumping Duties on Chinese Butyl Acrylate

The South Korean Trade Commission issued a final affirmative anti-dumping determination on Chinese butyl acrylate imports, proposing five-year duties of up to 19.17%. Specific company rates range from 8.32% for Shanghai Huayi to 19.17% for Pinghu Petrochemical, with a general rate of 18.69%. The measure increases export costs for key coating and adhesive raw materials. **(ChemNet Chemical Headlines)**

Sinochem International Narrows H1 2026 Losses as Chemical Exports Surge

Sinochem International reported its H1 2026 financial results, with net losses narrowing significantly from €113.74 million (886 million yuan) to €36.07 million (281 million yuan) on revenues of €3.02 billion (23.53 billion yuan). The recovery was driven by operational optimization, steady output in its carbon-three chain, and a 68% surge in overseas chemical exports. **(ChemNet Chemical Headlines)**

China Approves World-first Solid Tumor Car-t And Bispecific Adc

China granted simultaneous market approvals to breakthrough therapies from Biokin and Carsgen therapeutics, marking a pivotal shift in the domestic pharmaceutical landscape. Biokin's Lunkangyilongtuomab is the world's first Egrf $\times$ her3 bispecific antibody-drug conjugate, while Carsgen's Shuruji'aolunsa represents the first Car-t therapy targeting solid tumors. Both products are first-in-class innovations. **(National Medical Products Administration)**

Everest Medicines And Hainan Herui Partner On Budesonide Commercialization In China

Everest medicines announced a strategic commercialization collaboration with Hainan Herui relating to budesonide enteric capsules, further enhancing patient access to the medication across the Chinese market. The agreement allows Everest to leverage its established commercial infrastructure to expand the reach of Hainan Herui's innovative formulation. **(China Daily)**